Myeloid cell leukemia-1 regulates the cell growth and predicts prognosis in gastric cancer

International Journal of Oncology

Volumn 46, Issue 5, 2015, Pages 2154-2162

  Lee, Wan Sik ^a   Park, Young Lan ^a   Kim, Nuri ^a   Oh, Hyung Hoon ^a   Son, Dong Jun ^a   Kim, Mi Young ^a   Oak, Chan Young ^a   Chung, Cho Yun ^a   Park, Hyung Chul ^a   Kim, Jong Sun ^a   Myung, Dae Seong ^a   Cho, Sung Bum ^a   Joo, Young Eun ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Apoptosis; Myeloid cell leukemia 1; Prognosis; Proliferation; Stomach neoplasm

Indexed keywords

CASPASE 3; CASPASE 7; CELL CYCLE PROTEIN; CELL DIVISION CYCLE GENE 2; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; JANUS KINASE 2; MONOCLONAL ANTIBODY KI 67; PROTEIN MCL 1; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; MCL1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; APOPTOSIS; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CYTOPLASM; ENZYME INDUCTION; FEMALE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR VOLUME; AGED; BIOSYNTHESIS; FLOW CYTOMETRY; GENETIC TRANSFECTION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; STOMACH TUMOR; TUNEL ASSAY; WESTERN BLOTTING;

ADULT; AGED; APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROGNOSIS; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TRANSFECTION;

EID: 84925425603     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2890     Document Type: Article

References (38)

1. Guggenheim DE and Shah MA: Gastric cancer epidemiology and risk factors. J Surg Oncol 107: 230-236, 2013.
2. Krejs GJ: Gastric cancer: Epidemiology and risk factors. Dig Dis 28: 600-603, 2010.
3. Allan AL, Vantyghem SA, Tuck AB and Chambers AF: Tumor dormancy and cancer stem cells: Implications for the biology and treatment of breast cancer metastasis. Breast Dis 26: 87-98, 2006-2007.
4. Brábek J, Mierke CT, Rösel D, Veselý P and Fabry B: The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun Signal 8: 22, 2010.
5. Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science 331: 1559-1564, 2011.
6. Kiechle FL and Zhang X: Apoptosis: biochemical aspects and clinical implications. Clin Chim Acta 326: 27-45, 2002.
7. Schultz DR and Harrington WJ Jr: Apoptosis: Programmed cell death at a molecular level. Semin Arthritis Rheum 32: 345-369, 2003.
8. Ola MS, Nawaz M and Ahsan H: Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 351: 41-58, 2011.
9. Llambi F and Green DR: Apoptosis and oncogenesis: Give and take in the BCL-2 family. Curr Opin Genet Dev 21: 12-20, 2011.
10. Weyhenmeyer B, Murphy AC, Prehn JH and Murphy BM: Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer. Exp Oncol 34: 192-199, 2012.
11. Davids MS and Letai A: Targeting the B-cell lymphoma/ leukemia 2 family in cancer. J Clin Oncol 30: 3127-3135, 2012.
12. Thomas LW, Lam C and Edwards SW: Mcl-1; the molecular regulation of protein function. FEBS Lett 584: 2981-2989, 2010.
13. Akgul C: Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 66: 1326-1336, 2009.
14. Quinn BA, Dash R, Azab B, et al: Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 20: 1397-1411, 2011.
15. Zhang T, Zhao C, Luo L, Zhao H, Cheng J and Xu F: The expression of Mcl-1 in human cervical cancer and its clinical significance. Med Oncol 29: 1985-1991, 2012.
16. Luo L, Zhang T, Liu H, Lv T, Yuan D, Yao Y, Lv Y and Song Y: MiR-101 and Mcl-1 in non-small-cell lung cancer: Expression profile and clinical significance. Med Oncol 29: 1681-1686, 2012.
17. Henderson-Jackson EB, Helm J, Ghayouri M, Hakam A, Nasir A, Leon M, Bui M, Yeatman T and Coppola D: Correlation between Mcl-1 and pAKT protein expression in colorectal cancer. Int J Clin Exp Pathol 3: 768-774, 2010.
18. Likui W, Qun L, Wanqing Z, Haifeng S, Fangqiu L and Xiaojun L: Prognostic role of myeloid cell leukemia-1 protein (Mcl-1) expression in human gastric cancer. J Surg Oncol 100: 396-400, 2009.
19. Maeta Y, Tsujitani S, Matsumoto S, et al: Expression of Mcl-1 and p53 proteins predicts the survival of patients with T3 gastric carcinoma. Gastric Cancer 7: 78-84, 2004.
20. Tsujitani S, Saito H, Wakatsuki T, Ikeguchi M, Shirabe K, Morita M, Kakeji Y, Yano T and Maehara Y: Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer. Surg Today 42: 225-232, 2012.
21. Akagi H, Higuchi H, Sumimoto H, et al: Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer 16: 100-110, 2013.
22. Mandelin AM II and Pope RM: Myeloid cell leukemia-1 as a therapeutic target. Expert Opin Ther Targets 11: 363-373, 2007.
23. Perciavalle RM and Opferman JT: Delving deeper: MCL-1's contributions to normal and cancer biology. Trends Cell Biol 23: 22-29, 2013.
24. Hartman ML and Czyz M: Anti-apoptotic proteins on guard of melanoma cell survival. Cancer Lett 331: 24-34, 2013.
25. Bose P and Grant S: Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML). Leuk Res Rep 2: 12-14, 2013.
26. th edition. Springer-Verlag, New York, pp17-57, 2002.
27. Obexer P and Ausserlechner MJ: X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol 4: 197, 2014.
28. de Almagro MC and Vucic D: The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol 34: 200-211, 2012.
29. Kilbride SM and Prehn JH: Central roles of apoptotic proteins in mitochondrial function. Oncogene 32: 2703-2711, 2013.
30. Graña X and Reddy EP: Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211-219, 1995.
31. Soták M, Sumová A and Pácha J: Cross-talk between the circadian clock and the cell cycle in cancer. Ann Med 46: 221-232, 2014.
32. Fisher D, Krasinska L, Coudreuse D and NovákB: Phosphorylation network dynamics in the control of cell cycle transitions. J Cell Sci 125: 4703-4711, 2012.
33. Yu HG, Ai YW, Yu LL, et al: Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer 122: 433-443, 2008.
34. Choi IJ, Kim JS, Kim JM, Jung HC and Song IS: Effect of inhibition of extracellular signal-regulated kinase 1 and 2 pathway on apoptosis and bcl-2 expression in Helicobacter pylori-infected AGS cells. Infect Immun 71: 830-837, 2003.
35. McCubrey JA, Steelman LS, Bertrand FE, et al: GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 5: 2881-2911, 2014.
36. Amoyel M, Anderson AM and Bach EA: JAK/STAT pathway dysregulation in tumors: A Drosophila perspective. Semin Cell Dev Biol 28: 96-103, 2014.
37. Wacheck V, Cejka D, Sieghart W, Losert D, Strommer S, Crevenna R, Monia BP and Selzer E: Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol Ther 5: 1348-1354, 2006.
38. Zangemeister-Wittke U and Huwiler A: Antisense targeting of Mcl-1 has therapeutic potential in gastric cancer. Cancer Biol Ther 5: 1355-1356, 2006.